Potential Securities Fraud: Levi & Korsinsky Investigates Rezolute, Inc. (RZLT)

Core Viewpoint - Rezolute, Inc. is under investigation for potential violations of federal securities laws following disappointing results from its Phase 3 sunRIZE study evaluating ersodetug for congenital hyperinsulinism [1][2]. Group 1: Study Results - The Phase 3 sunRIZE study did not meet its primary endpoint, as results were "not statistically significant" compared to the placebo group, which showed a 40% improvement [2]. - The study also failed to meet its key secondary endpoint, which was similarly "not statistically significant" compared to the placebo [2]. - Management expressed disappointment and stated they are conducting a thorough evaluation to understand the study outcomes better [2]. Group 2: Stock Market Reaction - Following the announcement of the study results, Rezolute's stock price plummeted over 89%, opening at $1.21 per share [2].